Gravity Medical Technology has announced the launch of its next-generation stroke treatment devices: the Neutron aspiration catheter and the Supernova stent retriever. Early adoption has demonstrated the successful treatment of more than 60 patients worldwide, according to a company press release.
“Team Gravity is attempting to address one of the most important public health challenges of this generation,” said Dileep Yavagal (University of Miami, Miami, USA), principal investigator of the GRASSROOT trial.
“Gravity’s life-saving technology has demonstrated its ability to remove clots from the brain, which brings a much-needed technology to the rest of the world,” added Tudor Jovin (Cooper University, Camden, USA).
Leveraging advanced artificial intelligence (AI)-assisted computer simulation, Gravity claims to be at the forefront of developing next-generation devices that enhance effectiveness in treating stroke patients across various pathologies, making them substantially more accessible globally.
The Supernova stent retriever’s innovative design enhances the capture and removal of hard fibrin-rich (white) clots, which tend to present more in non-Caucasian populations. The Neutron aspiration catheter, with its enhanced kink resistance, ensures consistent aspiration power to effectively remove blood clots.
The release goes on to note that the Supernova device has shown clinically successful results in the GRASSROOT trial, presented at the iCURE/World Live Neurovascular Conference (WLNC) meeting (8–10 May, Istanbul, Turkey) earlier this year. The Supernova has demonstrated a high rate of first-pass successful recanalisation as well as achieving highly favourable revascularisation outcomes, according to Gravity.
“Stroke remains a leading cause of death and disability worldwide, and current technologies are not accessible to many patients in need,” said Gravity chief executive officer Kunakorn Atchaneeyasakul.
Gravity states that it aims to bridge this gap by bringing cutting-edge stroke treatment technologies to patients across the globe.
Both Supernova and Neutron have received approval from the Thai Food and Drug Administration (FDA) and are undergoing further clinical trials globally to validate their effectiveness and safety across diverse populations.
